Effects of inhibition of thromboxane A2 synthesis in aspirin-induced asthma

https://doi.org/10.1016/S0091-6749(87)80274-9Get rights and content

Since inhibition of cyclooxygenase precipitates asthmatic attacks in patients with aspirin idiosyncrasy, we have evaluated the effects of pharmacologic inhibition of thromboxane A2 (TXA2) synthetase, next to cyclooxygenase enzyme in arachidonic acid cascade. Sixteen patients with aspirin-induced asthma received increasing doses on 3 days (25 to 400 mg) of an imidazole derivative, OKY-046, which specifically blocks TXA2 synthetase. Twenty-three healthy control subjects received a single dose of 400 mg of OKY-046. In both patients and control subjects, the inhibitor at a dose of 400 mg produced (1) a pronounced fall in thromboxane B2 serum levels, (2) a rise in serum 6-keto-prostaglandin F, and (3) a depression in platelet aggregability to arachidonic acid and adenosine diphosphate. The drug, however, neither precipitated attacks of asthma nor impaired pulmonary function tests throughout a 24-hour observation period. Five patients, but none of the control subjects, developed transient nasal congestion about 1 hour after taking the drug. Thus, inhibition of TXA2 synthetase, contrary to inhibition of cyclooxygenase, does not affect bronchopulmonary function in patients with asthma and aspirin intolerance.

References (27)

  • SzczeklikA

    Analgesics, allergy, and asthma

    Drugs

    (1986)
  • SzczeklikA et al.

    Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients

    Br Med J

    (1975)
  • PleskowWW et al.

    Zomepirac sodium (Zomax) hypersensitivity in aspirin-sensitive asthmatics

    Am Rev Respir Dis

    (1984)
  • Cited by (12)

    • Pharmacological strategies for targeting platelet activation in asthma

      2019, Current Opinion in Pharmacology
      Citation Excerpt :

      This is a distinct syndrome, manifested as a hypersensitivity reaction, rather than allergy per se. There is evidence that in these patients, TXA2 inhibitors do not cause airway responses, and thus the activation pathway of platelets in AERD remains unknown [32]. Regardless of the efficacy of aspirin as an NSAID, separating these mode(s) of action from the well documented mechanism of aspirin treatment on haemostatic functions of platelets remains complicated.

    • Animal models of asthma

      1989, Pulmonary Pharmacology
    • Proposed mechanisms of aspirin sensitivity reactions

      1987, The Journal of Allergy and Clinical Immunology
    View all citing articles on Scopus
    1

    From the Department of Allergy and Clinical Immunology, Rzeszow's Department of Clinical Pharmacology, Copernicus Academy of Medicine, Cracow, Poland.

    View full text